PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3393296-6 1988 Infusion of the DOPA decarboxylase inhibitor carbidopa (5 micrograms in 1 microliter) 30 min prior to peripheral L-DOPA injection not only reduced contralateral circling but reversed the direction of turning 20 min after the L-DOPA injection. Levodopa 225-231 dopa decarboxylase Rattus norvegicus 16-34 4091838-5 1985 However, under the influence of alpha-methyl-dopa, an inhibitor of the dopadecarboxylase (aromatic L-amino acid decarboxylase, EC 4.1.1.28) the stimulatory effect of L-dopa on protein fucosylation was attenuated. Levodopa 166-172 dopa decarboxylase Rattus norvegicus 71-88 3713989-8 1986 This agrees with in vivo results of Alper and his colleagues who found an increased accumulation of L-3,4-dihydroxyphenylalanine (DOPA) in neuro-intermediate lobes of dehydrated rats after inhibition of DOPA-decarboxylase. Levodopa 100-128 dopa decarboxylase Rattus norvegicus 203-221 3713989-8 1986 This agrees with in vivo results of Alper and his colleagues who found an increased accumulation of L-3,4-dihydroxyphenylalanine (DOPA) in neuro-intermediate lobes of dehydrated rats after inhibition of DOPA-decarboxylase. Levodopa 130-134 dopa decarboxylase Rattus norvegicus 203-221 2998505-1 1985 Experiments on alert rats have shown that, with pre-inhibition of peripheral DOPA-decarboxylase, L-DOPA suppresses behavioral nociceptive reactions without changing hemodynamic ones. Levodopa 97-103 dopa decarboxylase Rattus norvegicus 77-95 2837907-8 1988 Benserazide (Bz), an inhibitor of the enzyme L-aromatic amino acid decarboxylase (AADC) that converts L-dopa to DA, significantly attenuated the natriuresis in HS rats but had no effect on GFR. Levodopa 102-108 dopa decarboxylase Rattus norvegicus 82-86 3379830-0 1988 Activities of aromatic L-amino acid decarboxylase with L-dopa as substrate in brush-border- and basolateral membranes and cytoplasm obtained from rat renal cortex. Levodopa 55-61 dopa decarboxylase Rattus norvegicus 23-49 3379830-1 1988 Activities of aromatic L-amino acid decarboxylase (AADC) with L-dopa as its substrate were determined in the plasma membranes and other cellular components isolated from rat renal cortex. Levodopa 62-68 dopa decarboxylase Rattus norvegicus 14-49 3379830-1 1988 Activities of aromatic L-amino acid decarboxylase (AADC) with L-dopa as its substrate were determined in the plasma membranes and other cellular components isolated from rat renal cortex. Levodopa 62-68 dopa decarboxylase Rattus norvegicus 51-55 6504328-0 1984 Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism. Levodopa 15-21 dopa decarboxylase Rattus norvegicus 90-108 6504328-0 1984 Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism. Levodopa 150-156 dopa decarboxylase Rattus norvegicus 90-108 6504328-1 1984 Dopamine (DA) elevations in rat striatum produced by combined administration of L-dopa and carbidopa were abolished when L-dopa was injected with NSD-1015, an inhibitor of central dopa-decarboxylase. Levodopa 80-86 dopa decarboxylase Rattus norvegicus 180-198 6504328-1 1984 Dopamine (DA) elevations in rat striatum produced by combined administration of L-dopa and carbidopa were abolished when L-dopa was injected with NSD-1015, an inhibitor of central dopa-decarboxylase. Levodopa 121-127 dopa decarboxylase Rattus norvegicus 180-198 4091838-5 1985 However, under the influence of alpha-methyl-dopa, an inhibitor of the dopadecarboxylase (aromatic L-amino acid decarboxylase, EC 4.1.1.28) the stimulatory effect of L-dopa on protein fucosylation was attenuated. Levodopa 166-172 dopa decarboxylase Rattus norvegicus 90-125 6983619-4 1982 AADC activities towards L-DOPA and L-5-HTP as substrates were also decreased significantly in almost all tissues of SC-treated rats. Levodopa 24-30 dopa decarboxylase Rattus norvegicus 0-4 6983619-0 1982 Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats. Levodopa 94-100 dopa decarboxylase Rattus norvegicus 53-79 6333583-4 1984 After this treatment AADC activities could be detected in the monkey serum by using both L-DOPA and L-5-HTP as substrates. Levodopa 89-95 dopa decarboxylase Rattus norvegicus 21-25 6333583-6 1984 Serum AADC was partially purified from monkey and compared with that of rat using both L-DOPA and L-5-HTP as substrates, but the ratio of the activities for the two substrates did not change significantly in each fraction during purification from either monkey or rat serum. Levodopa 87-93 dopa decarboxylase Rattus norvegicus 6-10 6205316-3 1984 It has been assumed, based on indirect evidence, that aromatic L-amino acid decarboxylase (L-AAD), the enzyme responsible for the conversion of L-5-hydroxytryptophan (5-HTP) to 5-HT as well as L-3,4-dihydroxyphenylalanine (L-dopa) to dopamine (DA), is ubiquitously distributed in most tissues of the body including the AP. Levodopa 223-229 dopa decarboxylase Rattus norvegicus 54-89 6135575-0 1983 A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine. Levodopa 171-199 dopa decarboxylase Rattus norvegicus 73-108 6135575-8 1983 Although AADC inhibition reduced the magnitude of the increases in serum dopamine levels following L-DOPA administration, no reduction in serum 3,4-dihydroxyphenylacetic acid levels was observed. Levodopa 99-105 dopa decarboxylase Rattus norvegicus 9-13 6983619-7 1982 Serum AADC activities were decreased drastically using both L-DOPA and L-5-HTP as substrates. Levodopa 60-66 dopa decarboxylase Rattus norvegicus 6-10 7205652-2 1981 L-Dopa administration increased DA concentrations in both lesioned and unlesioned sides; absolute increases were higher in control striata and pretreatment with carbidopa (an inhibitor of peripheral DDC) amplified the increases on both sides. Levodopa 0-6 dopa decarboxylase Rattus norvegicus 199-202 7195482-0 1981 Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Levodopa 87-93 dopa decarboxylase Rattus norvegicus 0-35 7407592-1 1980 In rats with unilateral nigrostriatal lesions, L-DOPA-induced dopamine increases in ipsilateral striata were further enhanced after inhibition of DOPA decarboxylase in cerebral microvessels by carbidopa. Levodopa 47-53 dopa decarboxylase Rattus norvegicus 146-164 28787702-0 2017 beta-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson"s rat by enhancing dopa decarboxylase activity. Levodopa 17-25 dopa decarboxylase Rattus norvegicus 161-179 5289371-0 1971 Decrease in liver aromatic L-amino-acid decarboxylase produced by chronic administration of L-dopa. Levodopa 92-98 dopa decarboxylase Rattus norvegicus 18-53 5289371-3 1971 In the present study, it was found that when L-dopa was administered to rats, the activity of liver aromatic L-amino-acid decarboxylase, the enzyme which catalyzes the conversion of dopa to dopamine, was reduced by as much as 50%. Levodopa 45-51 dopa decarboxylase Rattus norvegicus 100-135 956809-1 1976 In the L-Dopa treated rat, a decreased urinary output of free and conjugated dopamine and an increase in free and conjugated L-Dopa excretion after administration of decarboxylase-inhibiting drugs provide a good in vivo index of Dopa decarboxylase inhibition. Levodopa 7-13 dopa decarboxylase Rattus norvegicus 229-247 176961-4 1975 When peripheral Dopa-decarboxylase was inhibited, smaller doses of L-Dopa were effective. Levodopa 67-73 dopa decarboxylase Rattus norvegicus 16-34 1120949-2 1975 The administration of L-DOPA, 100 mg/kg i.p., after inhibition of peripheral dopa decarboxylase, disrupts the discrimination but not the acoidance behaviour, whereas the administration of the antipsychotic agent haloperidol (HPD), 0.125 mg/kg i.p., disrupts the avoidance behaviour but not the discrimination. Levodopa 22-28 dopa decarboxylase Rattus norvegicus 77-95 4732567-0 1973 Enhancement of the pharmacological action of 3,4-dihydroxy-L-phenylalanine(L-dopa) and reduction of dopa decarboxylase activity in rat liver after chronic treatment with L-dopa. Levodopa 170-176 dopa decarboxylase Rattus norvegicus 100-118 24997271-2 2014 The aim of this study was to test our hypothesis that DA is synthesized by monoenzymatic neurons, i.e. l-3,4-dihydroxyphenylalanine (l-DOPA), which produced in the monoenzymatic TH neurons is transported in the monoenzymatic AADC neurons for DA synthesis. Levodopa 103-131 dopa decarboxylase Rattus norvegicus 225-229 28166239-11 2017 After L-DOPA administration in MPTP-treated NHP, very poor conversion to DA was detected, suggesting that AADC in NHP nigrostriatal fibers is mainly responsible for L-DOPA to DA conversion. Levodopa 6-12 dopa decarboxylase Rattus norvegicus 106-110 28166239-11 2017 After L-DOPA administration in MPTP-treated NHP, very poor conversion to DA was detected, suggesting that AADC in NHP nigrostriatal fibers is mainly responsible for L-DOPA to DA conversion. Levodopa 165-171 dopa decarboxylase Rattus norvegicus 106-110 26830512-3 2016 Because AADC is a common enzyme catalyzing 5-hydroxytryptophan to serotonin and l-3,4-dihydroxyphenylalanine (l-dopa) to dopamine (DA), it seems likely that the ability of AADC cells using l-dopa to synthesize DA is also increased. Levodopa 80-108 dopa decarboxylase Rattus norvegicus 172-176 26830512-3 2016 Because AADC is a common enzyme catalyzing 5-hydroxytryptophan to serotonin and l-3,4-dihydroxyphenylalanine (l-dopa) to dopamine (DA), it seems likely that the ability of AADC cells using l-dopa to synthesize DA is also increased. Levodopa 110-116 dopa decarboxylase Rattus norvegicus 8-12 26830512-3 2016 Because AADC is a common enzyme catalyzing 5-hydroxytryptophan to serotonin and l-3,4-dihydroxyphenylalanine (l-dopa) to dopamine (DA), it seems likely that the ability of AADC cells using l-dopa to synthesize DA is also increased. Levodopa 189-195 dopa decarboxylase Rattus norvegicus 8-12 26830512-6 2016 However, following administration of a peripheral AADC inhibitor (carbidopa) with or without a monoamine oxidase inhibitor (pargyline) co-application, systemic administration of l-dopa resulted in ~94% of AADC cells becoming DA-immunopositive in the spinal cord below the lesion, whereas in normal or sham-operated rats none or very few of AADC cells became DA-immunopositive with the same treatment. Levodopa 178-184 dopa decarboxylase Rattus norvegicus 50-54 26830512-6 2016 However, following administration of a peripheral AADC inhibitor (carbidopa) with or without a monoamine oxidase inhibitor (pargyline) co-application, systemic administration of l-dopa resulted in ~94% of AADC cells becoming DA-immunopositive in the spinal cord below the lesion, whereas in normal or sham-operated rats none or very few of AADC cells became DA-immunopositive with the same treatment. Levodopa 178-184 dopa decarboxylase Rattus norvegicus 205-209 26830512-6 2016 However, following administration of a peripheral AADC inhibitor (carbidopa) with or without a monoamine oxidase inhibitor (pargyline) co-application, systemic administration of l-dopa resulted in ~94% of AADC cells becoming DA-immunopositive in the spinal cord below the lesion, whereas in normal or sham-operated rats none or very few of AADC cells became DA-immunopositive with the same treatment. Levodopa 178-184 dopa decarboxylase Rattus norvegicus 205-209 26622527-9 2015 In the rat plasma, TH and COMT peaked at 1 h, while AADC peaked at 5 h. In conclusion, the results of the present study indicate that the co-administration of L-dopa and beta-asarone may be used to maintain a stable striatal DA level within 48 h. In addition, this treatment may promote DA generation by AADC and reduce the metabolism of DA by COMT. Levodopa 159-165 dopa decarboxylase Rattus norvegicus 52-56 26622527-9 2015 In the rat plasma, TH and COMT peaked at 1 h, while AADC peaked at 5 h. In conclusion, the results of the present study indicate that the co-administration of L-dopa and beta-asarone may be used to maintain a stable striatal DA level within 48 h. In addition, this treatment may promote DA generation by AADC and reduce the metabolism of DA by COMT. Levodopa 159-165 dopa decarboxylase Rattus norvegicus 304-308 24997271-2 2014 The aim of this study was to test our hypothesis that DA is synthesized by monoenzymatic neurons, i.e. l-3,4-dihydroxyphenylalanine (l-DOPA), which produced in the monoenzymatic TH neurons is transported in the monoenzymatic AADC neurons for DA synthesis. Levodopa 133-139 dopa decarboxylase Rattus norvegicus 225-229 24997271-3 2014 Incubation of MBH in Krebs-Ringer solution with l-leucine, a competitive inhibitor of l-DOPA uptake, was used to prevent a hypothetical l-DOPA capture into AADC-containing neurons. Levodopa 136-142 dopa decarboxylase Rattus norvegicus 156-160 20407462-1 2011 The catecholamine, dopamine (DA), is synthesized from 3,4-dihydroxy-L-phenylalanine (L-DOPA) by aromatic L-amino acid decarboxylase (AADC). Levodopa 54-83 dopa decarboxylase Rattus norvegicus 105-131 23196068-4 2013 Since l-dopa could be decarboxylated by aromatic amino acid decarboxylase (AADC) present within both dopamine and serotonin neurons, it was hypothesized that serotonin neurons convert l-dopa into dopamine to generate excessive reactive oxygen species and quinoproteins that ultimately lead to serotonin neuron death. Levodopa 6-12 dopa decarboxylase Rattus norvegicus 75-79 23196068-4 2013 Since l-dopa could be decarboxylated by aromatic amino acid decarboxylase (AADC) present within both dopamine and serotonin neurons, it was hypothesized that serotonin neurons convert l-dopa into dopamine to generate excessive reactive oxygen species and quinoproteins that ultimately lead to serotonin neuron death. Levodopa 184-190 dopa decarboxylase Rattus norvegicus 75-79 22236652-1 2012 Peripheral aromatic amino acid decarboxylase (AADC) inhibitors, such as benserazide, are routinely used to potentiate the effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in Parkinson"s disease (PD) and in experimental models of PD. Levodopa 133-161 dopa decarboxylase Rattus norvegicus 46-50 22236652-1 2012 Peripheral aromatic amino acid decarboxylase (AADC) inhibitors, such as benserazide, are routinely used to potentiate the effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in Parkinson"s disease (PD) and in experimental models of PD. Levodopa 163-169 dopa decarboxylase Rattus norvegicus 46-50 22236652-8 2012 When L-DOPA treatment was delayed for 1, 2, or 3 h after benserazide, the rotational response declined suggesting loss of AADC inhibition. Levodopa 5-11 dopa decarboxylase Rattus norvegicus 122-126 20407462-1 2011 The catecholamine, dopamine (DA), is synthesized from 3,4-dihydroxy-L-phenylalanine (L-DOPA) by aromatic L-amino acid decarboxylase (AADC). Levodopa 54-83 dopa decarboxylase Rattus norvegicus 133-137 20407462-1 2011 The catecholamine, dopamine (DA), is synthesized from 3,4-dihydroxy-L-phenylalanine (L-DOPA) by aromatic L-amino acid decarboxylase (AADC). Levodopa 85-91 dopa decarboxylase Rattus norvegicus 105-131 20407462-1 2011 The catecholamine, dopamine (DA), is synthesized from 3,4-dihydroxy-L-phenylalanine (L-DOPA) by aromatic L-amino acid decarboxylase (AADC). Levodopa 85-91 dopa decarboxylase Rattus norvegicus 133-137 19449783-7 2009 In this case, L-tyrosine is transformed to L-DOPA in TH containing neurons that is followed by L-DOPA release and uptake to AADC containing neurons with a semi-specific membrane transporter of large neutral amino acids for DA synthesis. Levodopa 43-49 dopa decarboxylase Rattus norvegicus 124-128 20542064-0 2010 Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites. Levodopa 22-28 dopa decarboxylase Rattus norvegicus 87-122 20542064-2 2010 The anti-parkinsonian and pro-dyskinetic actions of L-DOPA are widely attributed to its conversion, by the enzyme aromatic L-amino acid decarboxylase (AADC), to dopamine. Levodopa 52-58 dopa decarboxylase Rattus norvegicus 123-149 20542064-2 2010 The anti-parkinsonian and pro-dyskinetic actions of L-DOPA are widely attributed to its conversion, by the enzyme aromatic L-amino acid decarboxylase (AADC), to dopamine. Levodopa 52-58 dopa decarboxylase Rattus norvegicus 151-155 18602388-2 2008 l-DOPA treatment (20-200 microM) increased the levels of dopamine by 226%-504% after 3-6 h of treatment and enhanced the activities of tyrosine hydroxylase (TH) and aromatic l-amino acid decarboxylase (AADC). Levodopa 0-6 dopa decarboxylase Rattus norvegicus 202-206 18602388-3 2008 l-DOPA (20-200 muM) treatment led to a 562%-937% increase in l-DOPA influx at 1 h, which inhibited the activity of TH, but not AADC, during the same period. Levodopa 0-6 dopa decarboxylase Rattus norvegicus 127-131 18602388-9 2008 One pathway involves l-DOPA directly entering the cells to convert dopamine through AADC activity (l-DOPA decarboxylation). Levodopa 21-27 dopa decarboxylase Rattus norvegicus 84-88 18602388-9 2008 One pathway involves l-DOPA directly entering the cells to convert dopamine through AADC activity (l-DOPA decarboxylation). Levodopa 99-105 dopa decarboxylase Rattus norvegicus 84-88 16504219-0 2006 L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase. Levodopa 0-28 dopa decarboxylase Rattus norvegicus 93-128 17241115-8 2007 Interestingly, Hsp70 induction, iNOS up-regulation and nitrotyrosine formation have been confirmed also in SN and striatum of rats treated with LD and carbidopa, this latter being an inhibitor of the peripheral DOPA decarboxylase. Levodopa 144-146 dopa decarboxylase Rattus norvegicus 211-229 17920284-4 2008 Intrastriatal inhibition of the enzyme aromatic amino acid decarboxylase (AADC) by benserazide prevented the appearance of l-DOPA-induced dyskinetic movements at the lesioned side. Levodopa 123-129 dopa decarboxylase Rattus norvegicus 74-78 17259019-6 2007 We found here that repeated administration of levodopa, added with the peripheral DOPA decarboxylase inhibitor carbidopa, increased dopamine turnover rate after lesioning the striatum with 6-hydroxydopamine. Levodopa 46-54 dopa decarboxylase Rattus norvegicus 82-100 16504219-2 2006 To map the DOPAergic system functionally, DOPA-induced c-Fos expression was detected under inhibition of central aromatic L-amino acid decarboxylase (AADC). Levodopa 11-15 dopa decarboxylase Rattus norvegicus 122-148 16504219-2 2006 To map the DOPAergic system functionally, DOPA-induced c-Fos expression was detected under inhibition of central aromatic L-amino acid decarboxylase (AADC). Levodopa 11-15 dopa decarboxylase Rattus norvegicus 150-154 16504219-3 2006 In rats treated with a central AADC inhibitor, DOPA significantly increased the number of c-Fos-positive nuclei in the paraventricular nuclei (PVN) and the nucleus tractus solitarii (NTS), and showed a tendency to increase in the supraoptic nuclei (SON), but not in the striatum. Levodopa 47-51 dopa decarboxylase Rattus norvegicus 31-35 16504219-4 2006 On the other hand, DOPA with a peripheral AADC inhibitor elevated the level of c-Fos-positive nuclei in the four regions, suggesting that DOPA itself induces c-Fos expression in the SON, PVN and NTS. Levodopa 19-23 dopa decarboxylase Rattus norvegicus 42-46 16504219-4 2006 On the other hand, DOPA with a peripheral AADC inhibitor elevated the level of c-Fos-positive nuclei in the four regions, suggesting that DOPA itself induces c-Fos expression in the SON, PVN and NTS. Levodopa 138-142 dopa decarboxylase Rattus norvegicus 42-46 16504219-5 2006 In rats treated with 6-hydroxydopamine (6-OHDA) to lesion the nigrostriatal dopamine (DA) pathway, DOPA significantly induced c-Fos expression in the four regions under the inhibition of peripheral AADC. Levodopa 99-103 dopa decarboxylase Rattus norvegicus 198-202 16269145-0 2006 Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration. Levodopa 179-207 dopa decarboxylase Rattus norvegicus 38-73 16269145-9 2006 The duration of FAS response to L-DOPA was sustained for a longer duration in rats grafted with PFVMAA cells than in those grafted with either control cells or cells with AADC alone. Levodopa 32-38 dopa decarboxylase Rattus norvegicus 171-175 15836622-4 2005 Infusion of this vector into the striatum of parkinsonian rats and monkeys improves L-DOPA responsiveness by improving AADC-mediated conversion of L-DOPA to dopamine. Levodopa 84-90 dopa decarboxylase Rattus norvegicus 119-123 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 94-122 dopa decarboxylase Rattus norvegicus 21-56 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 94-122 dopa decarboxylase Rattus norvegicus 58-62 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 94-122 dopa decarboxylase Rattus norvegicus 149-153 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 124-130 dopa decarboxylase Rattus norvegicus 21-56 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 124-130 dopa decarboxylase Rattus norvegicus 58-62 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 124-130 dopa decarboxylase Rattus norvegicus 149-153 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 233-239 dopa decarboxylase Rattus norvegicus 21-56 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 233-239 dopa decarboxylase Rattus norvegicus 58-62 16182609-5 2006 Using this strategy, aromatic L-amino acid decarboxylase (AADC) activity was retained so that l-3,4-dihydroxyphenylalanine (L-dopa), a substrate for AADC, could be converted to dopamine in the striatum and the therapeutic effects of L-dopa preserved, even after reduction of TH expression in the case of dopamine overproduction. Levodopa 233-239 dopa decarboxylase Rattus norvegicus 149-153 15836622-4 2005 Infusion of this vector into the striatum of parkinsonian rats and monkeys improves L-DOPA responsiveness by improving AADC-mediated conversion of L-DOPA to dopamine. Levodopa 147-153 dopa decarboxylase Rattus norvegicus 119-123 14565778-0 2003 The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study. Levodopa 115-121 dopa decarboxylase Rattus norvegicus 141-161 15380638-1 2004 Parkinson"s disease is a neurodegenerative disease and its symptoms are relieved by administration of L-dopa (LD), which is converted by neuronal aromatic L-aminoacid decarboxylase (AADC), restoring dopamine (DA) levels in surviving neurons. Levodopa 102-108 dopa decarboxylase Rattus norvegicus 155-180 15380638-1 2004 Parkinson"s disease is a neurodegenerative disease and its symptoms are relieved by administration of L-dopa (LD), which is converted by neuronal aromatic L-aminoacid decarboxylase (AADC), restoring dopamine (DA) levels in surviving neurons. Levodopa 102-108 dopa decarboxylase Rattus norvegicus 182-186 15380638-1 2004 Parkinson"s disease is a neurodegenerative disease and its symptoms are relieved by administration of L-dopa (LD), which is converted by neuronal aromatic L-aminoacid decarboxylase (AADC), restoring dopamine (DA) levels in surviving neurons. Levodopa 110-112 dopa decarboxylase Rattus norvegicus 155-180 15380638-1 2004 Parkinson"s disease is a neurodegenerative disease and its symptoms are relieved by administration of L-dopa (LD), which is converted by neuronal aromatic L-aminoacid decarboxylase (AADC), restoring dopamine (DA) levels in surviving neurons. Levodopa 110-112 dopa decarboxylase Rattus norvegicus 182-186 14701706-3 2004 Alveolar Type II cells express the enzyme aromatic-L-amino acid decarboxylase (AADC) and, when incubated with the dopamine precursor, 3-hydroxy-L-tyrosine (L-dopa), produce dopamine. Levodopa 156-162 dopa decarboxylase Rattus norvegicus 42-77 14701706-4 2004 Rats fed TSD, a precursor of L-dopa and dopamine, had increased urinary dopamine levels, which were inhibited by benserazide, an inhibitor of AADC. Levodopa 29-35 dopa decarboxylase Rattus norvegicus 142-146 15462205-8 2004 This is, probably, due to an L-tyrosine-induced competitive inhibition of the L-DOPA transport to monoenzymatic AADC neurons after its release from the monoenzymatic TH neurons. Levodopa 78-84 dopa decarboxylase Rattus norvegicus 112-116 14980733-1 2004 This study was aimed to test our hypothesis about dopamine (DA) synthesis by non-DAergic neurons expressing individual complementary enzymes of the DA synthetic pathway in cooperation, i.e. L-dihydroxyphenylalanine (L-DOPA) synthesized in tyrosine hydroxylase (TH)-expressing neurons is transported to aromatic L-amino acid decarboxylase (AADC)-expressing neurons for conversion to DA. Levodopa 190-214 dopa decarboxylase Rattus norvegicus 311-337 14980733-1 2004 This study was aimed to test our hypothesis about dopamine (DA) synthesis by non-DAergic neurons expressing individual complementary enzymes of the DA synthetic pathway in cooperation, i.e. L-dihydroxyphenylalanine (L-DOPA) synthesized in tyrosine hydroxylase (TH)-expressing neurons is transported to aromatic L-amino acid decarboxylase (AADC)-expressing neurons for conversion to DA. Levodopa 190-214 dopa decarboxylase Rattus norvegicus 339-343 14980733-1 2004 This study was aimed to test our hypothesis about dopamine (DA) synthesis by non-DAergic neurons expressing individual complementary enzymes of the DA synthetic pathway in cooperation, i.e. L-dihydroxyphenylalanine (L-DOPA) synthesized in tyrosine hydroxylase (TH)-expressing neurons is transported to aromatic L-amino acid decarboxylase (AADC)-expressing neurons for conversion to DA. Levodopa 216-222 dopa decarboxylase Rattus norvegicus 311-337 14980733-1 2004 This study was aimed to test our hypothesis about dopamine (DA) synthesis by non-DAergic neurons expressing individual complementary enzymes of the DA synthetic pathway in cooperation, i.e. L-dihydroxyphenylalanine (L-DOPA) synthesized in tyrosine hydroxylase (TH)-expressing neurons is transported to aromatic L-amino acid decarboxylase (AADC)-expressing neurons for conversion to DA. Levodopa 216-222 dopa decarboxylase Rattus norvegicus 339-343 14980733-8 2004 This contradiction is most probably explained by the L-tyrosine-induced competitive inhibition of the L-DOPA transport to the monoenzymatic AADC-neurons after its release from the monoenzymatic TH neurons. Levodopa 102-108 dopa decarboxylase Rattus norvegicus 140-144 14565778-6 2003 However, MPP(+) induced a transient, concentration-dependent rise of extracellular l-3,4-dihydroxyphenylalanine (l-DOPA), identified on the basis of dialysate analysis using several HPLC methods and its conversion to DA by purified l-DOPA decarboxylase (DDC). Levodopa 83-111 dopa decarboxylase Rattus norvegicus 232-252 14565778-6 2003 However, MPP(+) induced a transient, concentration-dependent rise of extracellular l-3,4-dihydroxyphenylalanine (l-DOPA), identified on the basis of dialysate analysis using several HPLC methods and its conversion to DA by purified l-DOPA decarboxylase (DDC). Levodopa 113-119 dopa decarboxylase Rattus norvegicus 232-252 12358737-1 2002 Aromatic L-amino acid decarboxylase (AADC) is necessary for conversion of L-DOPA to dopamine. Levodopa 74-80 dopa decarboxylase Rattus norvegicus 0-35 12676374-1 2003 Striatal neurons which are immunoreactive (ir) to aromatic L-amino-acid decarboxylase (AADC) or tyrosine hydrodroxylase (TH) may play a role in the decarboxylation of L-DOPA to dopamine (DA) in advanced stages of Parkinson"s disease (PD). Levodopa 167-173 dopa decarboxylase Rattus norvegicus 50-85 12676374-1 2003 Striatal neurons which are immunoreactive (ir) to aromatic L-amino-acid decarboxylase (AADC) or tyrosine hydrodroxylase (TH) may play a role in the decarboxylation of L-DOPA to dopamine (DA) in advanced stages of Parkinson"s disease (PD). Levodopa 167-173 dopa decarboxylase Rattus norvegicus 87-91 12676374-7 2003 The population of AADC-ir neurons may make a significant contribution to the effects of exogenous L-DOPA in advanced stages of PD. Levodopa 98-104 dopa decarboxylase Rattus norvegicus 18-22 12703659-1 2003 Benserazide is commonly used for Parkinson"s disease in combination with L-DOPA as a peripheral aromatic L-amino acid decarboxylase (AADC) inhibitor. Levodopa 73-79 dopa decarboxylase Rattus norvegicus 105-131 12703659-1 2003 Benserazide is commonly used for Parkinson"s disease in combination with L-DOPA as a peripheral aromatic L-amino acid decarboxylase (AADC) inhibitor. Levodopa 73-79 dopa decarboxylase Rattus norvegicus 133-137 12703659-8 2003 These results suggest that benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous L-DOPA. Levodopa 183-189 dopa decarboxylase Rattus norvegicus 59-63 12358737-1 2002 Aromatic L-amino acid decarboxylase (AADC) is necessary for conversion of L-DOPA to dopamine. Levodopa 74-80 dopa decarboxylase Rattus norvegicus 37-41 12358737-2 2002 Therefore, AADC gene therapy has been proposed to enhance pharmacological or gene therapies delivering L-DOPA. Levodopa 103-109 dopa decarboxylase Rattus norvegicus 11-15 12358737-3 2002 However, addition of AADC to the grafts of genetically modified cells expressing tyrosine hydroxylase (TH) and GTP cyclohydrolase 1 (GCH1), which produce L-DOPA in parkinsonian rats, resulted in decreased production of L-DOPA and dopamine owing to feedback inhibition of TH by dopamine. Levodopa 154-160 dopa decarboxylase Rattus norvegicus 21-25 11587490-4 2001 In the model Ro 04-5127 inhibited competitively the L-dopa clearance by AADC. Levodopa 52-58 dopa decarboxylase Rattus norvegicus 72-76 11965353-9 2002 During ontogenesis, the monoenzymatic TH- and AADC-containing neurons established axosomatic and axo-axonal junctions that might facilitate the L-DOPA transport from the former to the latter. Levodopa 144-150 dopa decarboxylase Rattus norvegicus 46-50 12047348-5 2002 These AADC neurones could uptake exogenously applied L-DOPA and formed dopamine. Levodopa 53-59 dopa decarboxylase Rattus norvegicus 6-10 10619466-2 2000 Acute administration of L-DOPA (25-200 mg/kg) dose-dependently inhibited the activity of aromatic L-amino acid decarboxylase (AADC) in the substantia nigra and corpus striatum. Levodopa 24-30 dopa decarboxylase Rattus norvegicus 98-124 11436352-4 2001 When the aromatic L-amino acid decarboxylase (AADC) gene was added as a third gene, in an attempt to increase the conversion of L-DOPA to dopamine, feedback inhibition by the end product, dopamine, on TH activity resulted. Levodopa 128-134 dopa decarboxylase Rattus norvegicus 9-44 11436352-4 2001 When the aromatic L-amino acid decarboxylase (AADC) gene was added as a third gene, in an attempt to increase the conversion of L-DOPA to dopamine, feedback inhibition by the end product, dopamine, on TH activity resulted. Levodopa 128-134 dopa decarboxylase Rattus norvegicus 46-50 11135014-1 2001 The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA. Levodopa 177-183 dopa decarboxylase Rattus norvegicus 41-59 11135014-1 2001 The centrally acting aromatic amino acid dopa decarboxylase (AADC) inhibitor, 3-hydroxybenzyl hydrazine (NSD-1015), is widely used to study the neurotransmitter-like actions of L-DOPA. Levodopa 177-183 dopa decarboxylase Rattus norvegicus 61-65 10773222-1 2000 The present study examined whether the O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA (3-OM-L-DOPA), inhibits neuronal (brain) and non-neuronal (liver and kidney) aromatic L-amino acid decarboxylase (AADC) activity. Levodopa 66-72 dopa decarboxylase Rattus norvegicus 178-204 10773222-1 2000 The present study examined whether the O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA (3-OM-L-DOPA), inhibits neuronal (brain) and non-neuronal (liver and kidney) aromatic L-amino acid decarboxylase (AADC) activity. Levodopa 66-72 dopa decarboxylase Rattus norvegicus 206-210 10619466-3 2000 The antiparkinsonian drugs budipine (10 mg/kg) and amantadine (40 mg/kg) enhanced AADC activity in these regions, and prevented or reversed AADC inhibition by L-DOPA. Levodopa 159-165 dopa decarboxylase Rattus norvegicus 140-144 11295535-2 2001 L-DOPA (L-dihydroxyphenylalanine), which is metabolized to dopamine by dopa decarboxylase, is the primary therapy for PD, but may also contribute to disease progression. Levodopa 0-6 dopa decarboxylase Rattus norvegicus 71-89 11295535-2 2001 L-DOPA (L-dihydroxyphenylalanine), which is metabolized to dopamine by dopa decarboxylase, is the primary therapy for PD, but may also contribute to disease progression. Levodopa 8-32 dopa decarboxylase Rattus norvegicus 71-89 11436352-6 2001 Gene transfer of the vesicular monoamine transporter was combined with AADC and produced genetically modified cells that can convert L-DOPA to dopamine and store it for gradual release. Levodopa 133-139 dopa decarboxylase Rattus norvegicus 71-75 11144954-8 2000 Understanding the source and localization of AADC is important in understanding the complications of L-dopa therapy and in designing rational therapeutic strategies for PD, including cellular transplantation and gene therapy. Levodopa 101-107 dopa decarboxylase Rattus norvegicus 45-49 10869844-1 2000 In a previous study, we described a population of striatal cells in the rat brain containing aromatic L-amino acid decarboxylase, the enzyme involved in the conversion of L-DOPA into dopamine. Levodopa 171-177 dopa decarboxylase Rattus norvegicus 93-128 10619466-2 2000 Acute administration of L-DOPA (25-200 mg/kg) dose-dependently inhibited the activity of aromatic L-amino acid decarboxylase (AADC) in the substantia nigra and corpus striatum. Levodopa 24-30 dopa decarboxylase Rattus norvegicus 126-130 9591841-1 1998 Tyrosine hydroxylase of catecholamine neurons catalyzes the synthesis of 3,4-dihydroxphenylalanine (DOPA), which is subsequently metabolized to dopamine by DOPA decarboxylase (DDC). Levodopa 100-104 dopa decarboxylase Rattus norvegicus 176-179 10191339-0 1999 Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats. Levodopa 106-135 dopa decarboxylase Rattus norvegicus 47-73 9591841-1 1998 Tyrosine hydroxylase of catecholamine neurons catalyzes the synthesis of 3,4-dihydroxphenylalanine (DOPA), which is subsequently metabolized to dopamine by DOPA decarboxylase (DDC). Levodopa 100-104 dopa decarboxylase Rattus norvegicus 156-174 10027744-3 1999 The results showed that Vmax values (in nmol mg protein(-1) h(-1)) for AADC, using L-DOPA as the substrate, in rat jejunal epithelial cells (127.3+/-11.4) were found to be 6-fold higher than in Caco-2 cells (22.5+/-2.6). Levodopa 83-89 dopa decarboxylase Rattus norvegicus 71-75 9853519-3 1998 Tyrosine hydroxylase (TH) catalyzes the synthesis of L-dopa, which must be converted to dopamine by aromatic L-amino acid decarboxylase (AADC). Levodopa 53-59 dopa decarboxylase Rattus norvegicus 109-135 9853519-3 1998 Tyrosine hydroxylase (TH) catalyzes the synthesis of L-dopa, which must be converted to dopamine by aromatic L-amino acid decarboxylase (AADC). Levodopa 53-59 dopa decarboxylase Rattus norvegicus 137-141 9710269-2 1998 Aromatic L-amino acid decarboxylase (AADC) is a regulated enzyme that catalyzes the decarboxylation of 3,4-dihydroxyphenylalanine (L-Dopa). Levodopa 131-137 dopa decarboxylase Rattus norvegicus 0-35 9710269-2 1998 Aromatic L-amino acid decarboxylase (AADC) is a regulated enzyme that catalyzes the decarboxylation of 3,4-dihydroxyphenylalanine (L-Dopa). Levodopa 131-137 dopa decarboxylase Rattus norvegicus 37-41 9710269-6 1998 The results suggest that the stimulation of AADC mRNA by amantadine may be one of its effects on dopamine metabolism that may have relevance for potentiation of L-Dopa therapy in Parkinsonism. Levodopa 161-167 dopa decarboxylase Rattus norvegicus 44-48 10343976-7 1998 The present findings support that one of the effects of L-deprenyl may be to facilitate the decarboxylation of L-DOPA by increasing the availability of AADC. Levodopa 111-117 dopa decarboxylase Rattus norvegicus 152-156 9591841-7 1998 The rate constant for the clearance of DOPA from brain (0.06 min(-1)) and earlier estimates of the rate constant of DDC activity in striatum (0.26 min(-1)) together predict that 80% of DOPA formed in normal rat striatum normally is available for dopamine synthesis. Levodopa 39-43 dopa decarboxylase Rattus norvegicus 116-119 9591841-7 1998 The rate constant for the clearance of DOPA from brain (0.06 min(-1)) and earlier estimates of the rate constant of DDC activity in striatum (0.26 min(-1)) together predict that 80% of DOPA formed in normal rat striatum normally is available for dopamine synthesis. Levodopa 185-189 dopa decarboxylase Rattus norvegicus 116-119 9591841-8 1998 It follows that modulation of DDC activity can influence the rate of DA synthesis by affecting the relative magnitude of the several fates of DOPA in living brain. Levodopa 142-146 dopa decarboxylase Rattus norvegicus 30-33 9349551-6 1997 Grafts containing aromatic L-amino acid decarboxylase produced less L-DOPA and dopamine as monitored by microdialysis. Levodopa 68-74 dopa decarboxylase Rattus norvegicus 18-53 9555017-5 1998 In response to NSD-1015 (an inhibitor of aromatic L-amino acid decarboxylase, AADC), 5-hydroxytryptophan (5-HTP) levels were substantially elevated in the SN grafted striata as compared with those in the sham grafted controls, which continued even after subsequent administration of L-3,4-dihydroxyphenylalanine (L-DOPA, 100 mg/kg i.p.). Levodopa 283-311 dopa decarboxylase Rattus norvegicus 78-82 9555017-5 1998 In response to NSD-1015 (an inhibitor of aromatic L-amino acid decarboxylase, AADC), 5-hydroxytryptophan (5-HTP) levels were substantially elevated in the SN grafted striata as compared with those in the sham grafted controls, which continued even after subsequent administration of L-3,4-dihydroxyphenylalanine (L-DOPA, 100 mg/kg i.p.). Levodopa 313-319 dopa decarboxylase Rattus norvegicus 78-82 9871440-1 1998 This study examines the hypothesis that glutamate tonically suppresses the activity of the enzyme aromatic L-amino acid decarboxylase (AADC), and hence the biosynthesis of dopamine, to explain how antagonists of glutamate receptors might potentiale the motor actions of L-DOPA in animal models of Parkinson"s disease. Levodopa 270-276 dopa decarboxylase Rattus norvegicus 98-133 9871440-1 1998 This study examines the hypothesis that glutamate tonically suppresses the activity of the enzyme aromatic L-amino acid decarboxylase (AADC), and hence the biosynthesis of dopamine, to explain how antagonists of glutamate receptors might potentiale the motor actions of L-DOPA in animal models of Parkinson"s disease. Levodopa 270-276 dopa decarboxylase Rattus norvegicus 135-139 9349551-7 1997 These findings indicate that not only is there sufficient aromatic L-amino acid decarboxylase near striatal grafts producing L-DOPA, but also the close proximity of the enzyme to tyrosine hydroxylase is detrimental for optimal dopamine production. Levodopa 125-131 dopa decarboxylase Rattus norvegicus 58-93 7697371-1 1994 The aim of the present study is to examine whether aromatic L-amino acid decarboxylase (AADC) catalyzes the conversion of exogenous L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine in serotonin neurons of the rat dorsal raphe nucleus. Levodopa 132-160 dopa decarboxylase Rattus norvegicus 60-86 8750961-1 1995 The efficacy of L-dihydroxyphenylalanine (L-DOPA) in ameliorating the symptoms of Parkinson"s disease (PD) is attributed to its conversion to dopamine (DA) by the enzyme aromatic L-amino-acid decarboxylase (AADC) in the striatum. Levodopa 16-40 dopa decarboxylase Rattus norvegicus 170-205 8750961-1 1995 The efficacy of L-dihydroxyphenylalanine (L-DOPA) in ameliorating the symptoms of Parkinson"s disease (PD) is attributed to its conversion to dopamine (DA) by the enzyme aromatic L-amino-acid decarboxylase (AADC) in the striatum. Levodopa 16-40 dopa decarboxylase Rattus norvegicus 207-211 8750961-1 1995 The efficacy of L-dihydroxyphenylalanine (L-DOPA) in ameliorating the symptoms of Parkinson"s disease (PD) is attributed to its conversion to dopamine (DA) by the enzyme aromatic L-amino-acid decarboxylase (AADC) in the striatum. Levodopa 42-48 dopa decarboxylase Rattus norvegicus 170-205 8750961-1 1995 The efficacy of L-dihydroxyphenylalanine (L-DOPA) in ameliorating the symptoms of Parkinson"s disease (PD) is attributed to its conversion to dopamine (DA) by the enzyme aromatic L-amino-acid decarboxylase (AADC) in the striatum. Levodopa 42-48 dopa decarboxylase Rattus norvegicus 207-211 9367815-6 1997 Kinetic constants Km and Vmax of recombinant AADC for the natural substrates L-dihydroxyphenylalanine and 5-hydroxytryptamine were 0.14 mM and 8444 U/mg, and 0.066 mM and 1813 U/mg, respectively. Levodopa 77-101 dopa decarboxylase Rattus norvegicus 45-49 8750961-2 1995 Although the site of this conversion in the DA-denervated striatum has yet to be identified, it has been proposed that L-DOPA could be converted to DA at non-dopaminergic sites containing AADC. Levodopa 119-125 dopa decarboxylase Rattus norvegicus 188-192 8750961-9 1995 These results strongly suggest the existence of a class of AADC-containing striatal cells that can form DA from exogenous L-DOPA in the rat. Levodopa 122-128 dopa decarboxylase Rattus norvegicus 59-63 7697371-1 1994 The aim of the present study is to examine whether aromatic L-amino acid decarboxylase (AADC) catalyzes the conversion of exogenous L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine in serotonin neurons of the rat dorsal raphe nucleus. Levodopa 132-160 dopa decarboxylase Rattus norvegicus 88-92 7697371-1 1994 The aim of the present study is to examine whether aromatic L-amino acid decarboxylase (AADC) catalyzes the conversion of exogenous L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine in serotonin neurons of the rat dorsal raphe nucleus. Levodopa 162-168 dopa decarboxylase Rattus norvegicus 60-86 7697371-1 1994 The aim of the present study is to examine whether aromatic L-amino acid decarboxylase (AADC) catalyzes the conversion of exogenous L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine in serotonin neurons of the rat dorsal raphe nucleus. Levodopa 162-168 dopa decarboxylase Rattus norvegicus 88-92 7697371-4 1994 The present result suggests that AADC decarboxylating L-5-hydroxytryptophan to serotonin in physiological conditions is also able to catalyze the in vivo decarboxylation of exogenous L-DOPA. Levodopa 183-189 dopa decarboxylase Rattus norvegicus 33-37 8510830-1 1993 Aromatic L-amino acid decarboxylase (AADC) decarboxylates L-DOPA and 5-hydroxytryptophan into dopamine and serotonin, respectively. Levodopa 58-64 dopa decarboxylase Rattus norvegicus 0-35 8246167-6 1993 Superfusion with the aromatic L-amino acid decarboxylase (AADC) inhibitor NSD-1055 (250 microM) abolished the inhibitory effects of L-DOPA, as did L-sulpiride (1 microM), an inhibitor of DA receptors of the D2 subtype. Levodopa 132-138 dopa decarboxylase Rattus norvegicus 21-56 8246167-6 1993 Superfusion with the aromatic L-amino acid decarboxylase (AADC) inhibitor NSD-1055 (250 microM) abolished the inhibitory effects of L-DOPA, as did L-sulpiride (1 microM), an inhibitor of DA receptors of the D2 subtype. Levodopa 132-138 dopa decarboxylase Rattus norvegicus 58-62 8108317-4 1993 When the dopa decarboxylase inhibitor alpha-methyldopa is added to the incubation medium, it reduces DA levels and conversely increases the amount of L-DOPA in a dose-dependent manner. Levodopa 150-156 dopa decarboxylase Rattus norvegicus 9-27 8510830-1 1993 Aromatic L-amino acid decarboxylase (AADC) decarboxylates L-DOPA and 5-hydroxytryptophan into dopamine and serotonin, respectively. Levodopa 58-64 dopa decarboxylase Rattus norvegicus 37-41 8422386-6 1993 On the reaction of AADC with L-3,4-dihydroxyphenylalanine (L-dopa), the absorption of PLP showed biphasic changes before reaching a steady-state. Levodopa 29-57 dopa decarboxylase Rattus norvegicus 19-23 8422386-6 1993 On the reaction of AADC with L-3,4-dihydroxyphenylalanine (L-dopa), the absorption of PLP showed biphasic changes before reaching a steady-state. Levodopa 59-65 dopa decarboxylase Rattus norvegicus 19-23 1801681-8 1991 These results suggest that fetal plasma L-dopa may be converted to dopamine by fetal kidney DDC, and that the dopamine is voided into the amniotic cavity in fetal urine. Levodopa 40-46 dopa decarboxylase Rattus norvegicus 92-95 1405340-2 1992 Proximal tubule cells produce dopamine after decarboxylation of L-DOPA via the enzyme aromatic L-amino acid decarboxylase (AADC). Levodopa 64-70 dopa decarboxylase Rattus norvegicus 95-121 1405340-2 1992 Proximal tubule cells produce dopamine after decarboxylation of L-DOPA via the enzyme aromatic L-amino acid decarboxylase (AADC). Levodopa 64-70 dopa decarboxylase Rattus norvegicus 123-127 1465439-1 1992 Aromatic L-amino acid decarboxylase (AADC, EC 4.1.1.28) catalyzes the decarboxylation of L-dopa to dopamine in catecholamine cells and 5-hydroxytryptophan to serotonin in serotonin-producing neurons. Levodopa 89-95 dopa decarboxylase Rattus norvegicus 0-35 1465439-1 1992 Aromatic L-amino acid decarboxylase (AADC, EC 4.1.1.28) catalyzes the decarboxylation of L-dopa to dopamine in catecholamine cells and 5-hydroxytryptophan to serotonin in serotonin-producing neurons. Levodopa 89-95 dopa decarboxylase Rattus norvegicus 37-41 2081822-1 1990 By indirect immunohistochemistry, the present study examined the distribution of neuronal structures in the cat medulla oblongata, pons, and midbrain, showing immunoreactivity to aromatic L-amino acid decarboxylase (AADC), which catalyzes the conversion of L-3, 4-dihydroxyphenylalanine (L-DOPA) to dopamine, and 5-hydroxytryptophan to serotonin (5HT). Levodopa 288-294 dopa decarboxylase Rattus norvegicus 188-214 2033120-1 1991 Aromatic L-amino acid decarboxylase (AADC), the enzyme that converts L-dopa to dopamine, displayed species-specific differences in both activity and immunoreactivity in the cerebellum, olfactory bulb, and adrenal glands of three rodent species, the hamster, rat, and mouse. Levodopa 69-75 dopa decarboxylase Rattus norvegicus 0-35 1797228-1 1991 Aromatic L-amino acid decarboxylase (AADC) is responsible for the conversion of L-3,4-dihydroxyphenylalanine (L-DOPA) and L-5-hydroxytryptophan to dopamine and serotonin, respectively, which are important neurotransmitters. Levodopa 80-108 dopa decarboxylase Rattus norvegicus 0-35 1797228-1 1991 Aromatic L-amino acid decarboxylase (AADC) is responsible for the conversion of L-3,4-dihydroxyphenylalanine (L-DOPA) and L-5-hydroxytryptophan to dopamine and serotonin, respectively, which are important neurotransmitters. Levodopa 80-108 dopa decarboxylase Rattus norvegicus 37-41 1797228-1 1991 Aromatic L-amino acid decarboxylase (AADC) is responsible for the conversion of L-3,4-dihydroxyphenylalanine (L-DOPA) and L-5-hydroxytryptophan to dopamine and serotonin, respectively, which are important neurotransmitters. Levodopa 110-116 dopa decarboxylase Rattus norvegicus 0-35 1797228-1 1991 Aromatic L-amino acid decarboxylase (AADC) is responsible for the conversion of L-3,4-dihydroxyphenylalanine (L-DOPA) and L-5-hydroxytryptophan to dopamine and serotonin, respectively, which are important neurotransmitters. Levodopa 110-116 dopa decarboxylase Rattus norvegicus 37-41 2081822-1 1990 By indirect immunohistochemistry, the present study examined the distribution of neuronal structures in the cat medulla oblongata, pons, and midbrain, showing immunoreactivity to aromatic L-amino acid decarboxylase (AADC), which catalyzes the conversion of L-3, 4-dihydroxyphenylalanine (L-DOPA) to dopamine, and 5-hydroxytryptophan to serotonin (5HT). Levodopa 288-294 dopa decarboxylase Rattus norvegicus 216-220 2154126-1 1990 The enzyme L-amino acid decarboxylase (L-AADC), found in abundance in rat proximal tubule cell cytosol, converts L-dopa to dopamine. Levodopa 113-119 dopa decarboxylase Rattus norvegicus 41-45 2154126-8 1990 Carbidopa, an inhibitor of L-AADC, abolished the L-dopa-induced inhibition of nystatin-stimulated QO2 in cells from HS rats and was without significant effect in cells from LS rats. Levodopa 49-55 dopa decarboxylase Rattus norvegicus 29-33 1972967-9 1990 Metabolic conversion of L-dopa by AADC is thus preserved in the case of an approach via the basolateral side of the proximal tubular cells. Levodopa 24-30 dopa decarboxylase Rattus norvegicus 34-38 34313482-3 2021 Treatment with L-dihydroxyphenylalanine, not tyrosine, caused the production of dopamine in the incubation of INS-1 cells (rat islet beta cell line) and primary isolated islets, which was blocked by AADC inhibitor NSD-1015. Levodopa 15-39 dopa decarboxylase Rattus norvegicus 199-203